Join
Live feed
·
PRReleasevia Quantisnow
Kodiak Sciences Inc logo

Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

ByQuantisnow·Wall Street's wire, on your screen.
KOD· Kodiak Sciences Inc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KOD (Kodiak Sciences Inc) and more on Quantisnow.